[go: up one dir, main page]

PE20160043A1 - Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2 - Google Patents

Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2

Info

Publication number
PE20160043A1
PE20160043A1 PE2015002532A PE2015002532A PE20160043A1 PE 20160043 A1 PE20160043 A1 PE 20160043A1 PE 2015002532 A PE2015002532 A PE 2015002532A PE 2015002532 A PE2015002532 A PE 2015002532A PE 20160043 A1 PE20160043 A1 PE 20160043A1
Authority
PE
Peru
Prior art keywords
dosage form
pharmaceutical dosage
bcl
inhibitor
family
Prior art date
Application number
PE2015002532A
Other languages
English (en)
Inventor
Martin Knobloch
Drazen Kostelac
Norbert Steiger
Claudia Packhaeuser
Bernd Liepold
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160043(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of PE20160043A1 publication Critical patent/PE20160043A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una forma de dosificacion farmaceutica que comprende un producto de dispersion solida que comprende N-(4-(4-( (2-( 4-clorofenil)-5,5-dimetil-1-ciclohex-1-en-1- il)metil)piperazin-1-il)benzoil)-4-(((1R)-3-(morfolin-4-il)-1-((fenilsulfanil)metil)propil)amino)-3-(trifluorometil)sulfonil)bencenosulfonamida(navitoclax, ABT-263, A-855071, o una sal, hidrato o solvato de la misma, al menos un polimero farmaceuticamente aceptable, y al menos un solubilizante farmaceutica mente aceptable. La invencion ademas esta dirigida a procesos para preparar la forma de dosificacion farmaceutica y para usar la forma de dosificacion para tratar trastornos proliferativos
PE2015002532A 2009-06-08 2010-06-08 Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2 PE20160043A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18513009P 2009-06-08 2009-06-08

Publications (1)

Publication Number Publication Date
PE20160043A1 true PE20160043A1 (es) 2016-02-11

Family

ID=43063251

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015002532A PE20160043A1 (es) 2009-06-08 2010-06-08 Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2
PE2011002058A PE20121084A1 (es) 2009-06-08 2010-06-08 Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011002058A PE20121084A1 (es) 2009-06-08 2010-06-08 Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2

Country Status (37)

Country Link
US (6) US9642796B2 (es)
EP (3) EP2440177B1 (es)
JP (2) JP5872459B2 (es)
KR (2) KR101751216B1 (es)
CN (2) CN102802606A (es)
AR (2) AR077021A1 (es)
AU (1) AU2010258367B2 (es)
BR (2) BRPI1012831B1 (es)
CA (1) CA2763441C (es)
CL (1) CL2011003054A1 (es)
CO (1) CO6480964A2 (es)
CR (1) CR20170037A (es)
CY (1) CY1119663T1 (es)
DK (2) DK2440177T3 (es)
DO (2) DOP2011000375A (es)
EC (1) ECSP12011580A (es)
ES (2) ES2551860T3 (es)
HR (2) HRP20151342T1 (es)
HU (2) HUE025638T2 (es)
IL (2) IL216494A (es)
LT (1) LT2982366T (es)
MX (1) MX2011013164A (es)
MY (1) MY159824A (es)
NO (1) NO2982366T3 (es)
NZ (1) NZ597241A (es)
PE (2) PE20160043A1 (es)
PL (2) PL2982366T3 (es)
PT (2) PT2440177E (es)
RU (2) RU2568599C2 (es)
SG (1) SG176264A1 (es)
SI (2) SI2440177T1 (es)
SM (1) SMT201500317B (es)
TW (2) TWI471321B (es)
UA (1) UA104471C2 (es)
UY (1) UY32695A (es)
WO (1) WO2010143074A2 (es)
ZA (1) ZA201108853B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
SG2014013502A (en) 2010-06-09 2014-05-29 Abbvie Inc Solid dispersions containing kinase inhibitors
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
RU2598345C2 (ru) * 2010-10-29 2016-09-20 Эббви Инк. Твердые дисперсии, содержащие средства, вызывающие апоптоз
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
TWI535701B (zh) 2010-11-23 2016-06-01 艾伯維巴哈馬有限公司 使用選擇性ｂｃｌ－２抑制劑之治療方法
NZ610151A (en) 2010-11-23 2015-06-26 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
KR102191562B1 (ko) * 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2014160071A1 (en) * 2013-03-14 2014-10-02 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
WO2015051252A1 (en) * 2013-10-03 2015-04-09 Duke University Compositions and methods for treating cancer with jak2 activity
US20170021033A1 (en) * 2014-03-12 2017-01-26 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
BR112016024421A2 (pt) * 2014-06-18 2017-08-15 Chugai Pharmaceutical Co Ltd composição farmacêutica, cápsula e uso da composição farmacêutica
CN105616419A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法
CN113925833A (zh) 2016-02-29 2022-01-14 豪夫迈·罗氏有限公司 包含酪氨酸蛋白激酶抑制剂的剂型组合物
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
US11872237B2 (en) 2018-12-28 2024-01-16 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and preparation method thereof
US11285159B2 (en) 2019-11-05 2022-03-29 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax
JP2023514750A (ja) * 2020-02-24 2023-04-07 グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド Ｂｃｌ２阻害剤を含むホットメルト押出し固体分散体
CN114533677A (zh) * 2020-11-25 2022-05-27 苏州亚盛药业有限公司 固体分散体、制剂、其制备方法及其应用
MX2023008155A (es) * 2021-01-08 2023-07-24 Syros Pharmaceuticals Inc Regimenes de tratamiento con dosis fijas de tamibaroteno.
CN113520995B (zh) * 2021-08-16 2023-03-10 海南鑫开源医药科技有限公司 一种离子敏感型眼用原位凝胶、其制备方法及应用
WO2023172958A1 (en) * 2022-03-08 2023-09-14 Onkosxcel Therapeutics, Llc Stable formulations of talabostat

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
GB9309509D0 (en) * 1993-05-07 1993-06-23 Merck Patent Gmbh Thrombin inhibitors
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
DE69434626D1 (de) * 1993-11-17 2006-04-20 Athena Neurosciences Inc Transparente flüssigkeit zur verabreichung von verkapselten medikamenten
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20020055631A1 (en) * 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
DE60113731T2 (de) * 2001-01-31 2006-06-29 Pfizer Products Inc., Groton Als inhibitoren von pde4-isozymen geeignete etherderivate
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
PT1471887E (pt) * 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
US20050163835A1 (en) * 2002-02-26 2005-07-28 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
TWI262077B (en) * 2002-04-29 2006-09-21 Merck & Co Inc Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
US7318503B2 (en) 2004-04-26 2008-01-15 Akebono Corporation (North America) Pad retaining clips
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
DK1888550T3 (da) * 2005-05-12 2014-09-29 Abbvie Bahamas Ltd Apoptosepromotorer
CN1706371B (zh) 2005-05-27 2010-11-10 沈阳药科大学 一种高效的马蔺子素制剂及其制备方法
SI1933809T1 (sl) 2005-10-11 2012-08-31 Yissum Res Dev Co Sestavki za mazalno dajanje
US20070104780A1 (en) * 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
US7151188B1 (en) 2005-11-16 2006-12-19 General Electric Company Process for the production of mercaptoalkylalkoxysilanes
EP2037912A2 (en) * 2006-05-15 2009-03-25 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
US20080004286A1 (en) * 2006-06-30 2008-01-03 Schering Corporation Method of Using Substituted Piperidines that Increase P53 Activity
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
WO2008030836A2 (en) * 2006-09-05 2008-03-13 Abbott Laboratories Bcl inhibitors treating platelet excess
WO2008064116A2 (en) * 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
RU2351352C2 (ru) 2007-04-09 2009-04-10 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Твердая нанокомпозиция для доставки биологически активных веществ
US8536157B2 (en) 2007-04-13 2013-09-17 The University Of Melbourne Non-steroidal compounds
CN101861165A (zh) * 2007-10-12 2010-10-13 麻省理工学院 疫苗纳米技术
EP2219651A1 (en) * 2007-12-06 2010-08-25 Abbott Laboratories Oral compositions of abt-263 for treating cancer
CN101220008B (zh) 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US20100280031A1 (en) 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
CA2764187A1 (en) * 2009-06-18 2010-12-23 Abbott Laboratories Stable nanoparticulate drug suspension
KR20120085781A (ko) 2009-09-20 2012-08-01 아보트 러보러터리즈 Ｂｃｌ-２ 단백질 관련 질환을 치료하는데 사용하기 위한 ａｂｔ-２６３ 결정 형태 및 용매화물
SG181916A1 (en) 2009-12-22 2012-08-30 Abbott Lab Abt-263 capsule
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备
JP6095678B2 (ja) 2011-11-11 2017-03-15 エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド 薬剤パッケージ用の不動態化、ｐＨ保護又は滑性皮膜、被覆プロセス及び装置

Also Published As

Publication number Publication date
BRPI1012831A2 (pt) 2018-03-06
LT2982366T (lt) 2017-11-27
AU2010258367B2 (en) 2014-05-01
IL238477A0 (en) 2015-06-30
HK1169613A1 (en) 2013-02-01
TWI471321B (zh) 2015-02-01
EP2982366B1 (en) 2017-09-13
HUE035727T2 (en) 2018-05-28
ZA201108853B (en) 2012-08-29
IL238477A (en) 2017-01-31
WO2010143074A2 (en) 2010-12-16
JP5872459B2 (ja) 2016-03-01
ECSP12011580A (es) 2012-02-29
CO6480964A2 (es) 2012-07-16
US9642796B2 (en) 2017-05-09
EP2982366A1 (en) 2016-02-10
HK1220902A1 (en) 2017-05-19
MY159824A (en) 2017-02-15
WO2010143074A3 (en) 2011-02-17
UY32695A (es) 2010-12-31
DOP2011000375A (es) 2011-12-31
IL216494A (en) 2016-03-31
HRP20151342T1 (hr) 2016-01-01
CN102802606A (zh) 2012-11-28
HUE025638T2 (en) 2016-04-28
KR20170073714A (ko) 2017-06-28
ES2651307T3 (es) 2018-01-25
BR122018076978B1 (pt) 2021-08-31
KR101751216B1 (ko) 2017-06-28
AR109816A2 (es) 2019-01-23
EP3272334A1 (en) 2018-01-24
AU2010258367A1 (en) 2012-01-19
SG176264A1 (en) 2012-01-30
CA2763441A1 (en) 2010-12-16
RU2568599C2 (ru) 2015-11-20
CY1119663T1 (el) 2018-04-04
JP2016121159A (ja) 2016-07-07
US20210093649A1 (en) 2021-04-01
PL2440177T3 (pl) 2016-03-31
SMT201500317B (it) 2016-02-25
HRP20171902T1 (hr) 2018-01-26
PE20121084A1 (es) 2012-09-13
US20100310648A1 (en) 2010-12-09
US20190269704A1 (en) 2019-09-05
ES2551860T3 (es) 2015-11-24
NZ597241A (en) 2014-01-31
TW201103925A (en) 2011-02-01
NO2982366T3 (es) 2018-02-10
CN106074391A (zh) 2016-11-09
BRPI1012831B1 (pt) 2021-05-18
US20170189426A1 (en) 2017-07-06
CR20170037A (es) 2017-04-17
RU2015141869A (ru) 2018-12-29
US20240197757A1 (en) 2024-06-20
PT2440177E (pt) 2015-12-01
DOP2017000057A (es) 2017-04-16
EP3272334B1 (en) 2019-03-06
KR101791404B1 (ko) 2017-10-30
TW201529572A (zh) 2015-08-01
DK2440177T3 (en) 2015-12-21
RU2015141869A3 (es) 2019-04-19
RU2011154143A (ru) 2013-07-20
JP2012529490A (ja) 2012-11-22
SI2440177T1 (sl) 2016-01-29
PT2982366T (pt) 2017-12-21
RU2711359C2 (ru) 2020-01-16
KR20120027049A (ko) 2012-03-20
DK2982366T3 (en) 2018-01-02
MX2011013164A (es) 2012-04-20
AR077021A1 (es) 2011-07-27
EP2440177B1 (en) 2015-09-16
JP6129999B2 (ja) 2017-05-17
UA104471C2 (uk) 2014-02-10
PL2982366T3 (pl) 2018-06-29
CL2011003054A1 (es) 2012-07-20
CA2763441C (en) 2018-01-02
EP2440177A2 (en) 2012-04-18
IL216494A0 (en) 2012-01-31
US20220110951A1 (en) 2022-04-14
SI2982366T1 (en) 2018-01-31
TWI540132B (zh) 2016-07-01

Similar Documents

Publication Publication Date Title
PE20160043A1 (es) Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2
MX2010006260A (es) Composiciones orales de abt-263 para tratar cancer.
NZ585085A (en) Method of treating arthritis using arylsulfonamide compounds
CY1114242T1 (el) Μια διεργασια για την παρασκευη του υποκινητη αποπτωσης αβτ-263
CL2012001133A1 (es) Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo.
PE20200334A1 (es) Preparacion solida para administracion oral
CL2019003857A1 (es) Composiciones y métodos de uso de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida solicitudes relacionadas.
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
JP2013531028A5 (es)
JP2009541443A5 (es)
EA202191061A1 (ru) фармацевтическая композиция для перорального введения, содержащая диметиламинA или его соль
EP4275707A3 (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
ECSP22098275A (es) Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina
EP4249513A3 (en) Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
PE20191240A1 (es) Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios
AR109652A1 (es) Métodos para utilizar agonistas de fxr
AR059838A1 (es) Formulaciones para dosis estabilizantes de estatina
CR20110663A (es) Forma de dosificaciën farmacuutica para administraciën oral de un inhibidor de la familia bcl 2
CY1117296T1 (el) Φαρμακευτικη μορφη δοσολογιας για απο του στοματος χορηγηση ενος αναστολεα της οικογενειας bcl-2
TH127003A (th) รูปฟอร์มขนาดใช้ในทางเภสัชกรรมสำหรับการดำเนินการให้ผ่านทางปากของสารยับยั้ง bcl-2 แฟมมิลี
PH12016502285A1 (en) Pharmaceutical composition for oral administration
AR082876A1 (es) Sales de bromhidrato de una pirazolilaminoquinazolina
AR099283A1 (es) Composiciones y métodos para el tratamiento de enfermedades virales con moduladores de la pde4
AR077501A1 (es) Una composicion farmaceutica unitaria, administrable por via oral, que comprende la combinacion de los compuestos (alfa s)-n,n-dimetil-alfa-[2-(1-naftaleniloxi)etil]benzeno-metanamina y 1-[[3-(4,7-dihidro-1-metil-7-oxo-3-propil-1h-pirazolo[4,3-d]pirimidin-5-il)-4-etoxifenil]sulfonil]-4-metilpiperazi